Clinical Features of Bone Complications and Prognostic Value of Bone Lesions Detected by X-ray Skeletal Survey in Previously Untreated Patients with Multiple Myeloma

被引:9
作者
Li, Si-dan [4 ]
Wang, Ya-fei [1 ,2 ,3 ]
Qi, Jun-yuan [1 ,2 ,3 ]
Qiu, Lu-gui [1 ,2 ,3 ]
机构
[1] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Hosp Blood Dis, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
[4] Capital Med Univ, Beijing Childrens Hosp, Hematol Ctr, Beijing 100045, Peoples R China
关键词
Multiple myeloma; Myeloma bone disease; Bone lesions; Prognosis; STAGING SYSTEM; OSTEOPROTEGERIN; DISEASE; MARROW; VAD;
D O I
10.1007/s12288-010-0033-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma is usually associated with the presence of lytic bone lesions. We reviewed the clinical and laboratory features of patients with newly diagnosed myeloma bone disease and evaluated the prognostic significance of different X-ray image patterns in symptomatic MM patients. We retrospectively reviewed 260 patients with newly diagnosed MM. X-ray image patterns of patients were correlated with hematologic parameters, therapeutic reaction and patient survival. Patients with the X-ray imaging pattern of grade 2-4 had significantly higher marrow plasma cells levels, marrow CD138(+) D38(+) cell percentage, ECOG performance score, and serum IL-6 level than grade 0-1. Univariate analysis demonstrated that skeletal lytic changes associated with rapid progression. There is a high incidence of myeloma bone disease (MBD) in patients of MM in China. Patients of extensive bone lesions have more severe alterations in hematologic parameters than do those without bone lesions and severe bone lesions is an important adverse prognostic factor associated with a short TTP.
引用
收藏
页码:83 / 88
页数:6
相关论文
共 21 条
  • [1] VAD-BASED REGIMENS AS PRIMARY-TREATMENT FOR MULTIPLE-MYELOMA
    ALEXANIAN, R
    BARLOGIE, B
    TUCKER, S
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 1990, 33 (02) : 86 - 89
  • [2] Bettini R, 1989, Recenti Prog Med, V80, P300
  • [3] DEGRAMONT A, 1985, SCAND J HAEMATOL, V34, P78
  • [4] Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma
    Dimopoulos, MA
    Pouli, A
    Zervas, K
    Grigoraki, V
    Symeonidis, A
    Repoussis, P
    Mitsouli, C
    Papanastasiou, C
    Margaritis, D
    Tokmaktsis, A
    Katodritou, I
    Kokkini, G
    Terpos, E
    Vyniou, N
    Tzilianos, M
    Chatzivassili, A
    Kyrtsonis, MC
    Panayiotidis, P
    Maniatis, A
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (07) : 1039 - 1044
  • [5] International uniform response criteria for multiple myeloma
    Durie, B. G. M.
    Harousseau, J-L
    Miguel, J. S.
    Blade, J.
    Barlogie, B.
    Anderson, K.
    Gertz, M.
    Dimopoulos, M.
    Westin, J.
    Sonneveld, P.
    Ludwig, H.
    Gahrton, G.
    Beksac, M.
    Crowley, J.
    Belch, A.
    Boccadaro, M.
    Turesson, I.
    Joshua, D.
    Vesole, D.
    Kyle, R.
    Alexanian, R.
    Tricot, G.
    Attal, M.
    Merlini, G.
    Powles, R.
    Richardson, P.
    Shimizu, K.
    Tosi, P.
    Morgan, G.
    Rajkumar, S. V.
    [J]. LEUKEMIA, 2006, 20 (09) : 1467 - 1473
  • [6] DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO
  • [7] 2-U
  • [8] International staging system for multiple myeloma
    Greipp, PR
    San Miguel, J
    Durie, BGM
    Crowley, JJ
    Barlogie, B
    Bladé, J
    Boccadoro, M
    Child, JA
    Harousseau, JL
    Kyle, RA
    Lahuerta, JJ
    Ludwig, H
    Morgan, G
    Powles, R
    Shimizu, K
    Shustik, C
    Sonneveld, P
    Tosi, P
    Turesson, I
    Westin, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) : 3412 - 3420
  • [9] VARIATIONS IN THE ROENTGEN APPEARANCE OF THE SKELETAL SYSTEM IN MYELOMA
    HEISER, S
    SCHWARTZMAN, JJ
    [J]. RADIOLOGY, 1952, 58 (02) : 178 - 191
  • [10] Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
    Hsu, HL
    Lacey, DL
    Dunstan, CR
    Solovyev, I
    Colombero, A
    Timms, E
    Tan, HL
    Elliott, G
    Kelley, MJ
    Sarosi, I
    Wang, L
    Xia, XZ
    Elliott, R
    Chiu, L
    Black, T
    Scully, S
    Capparelli, C
    Morony, S
    Shimamoto, G
    Bass, MB
    Boyle, WJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) : 3540 - 3545